Skip to main content
SpringerLink
Log in

Radionuclide Leptomeningeal Metastasis Therapy Trials

  • Chapter
  • First Online:
Radiopharmaceuticals in the Management of Leptomeningeal Metastasis

  • 126 Accesses

Abstract

The rationales for published intrathecal radionuclide for leptomeningeal metastasis (LM) therapy trials with radiopharmaceuticals are reviewed. The radioactivity dosing schemes, efficacy, and toxicity profiles are compared. The potential use of radiation dosimetry to guide intrathecal radionuclide therapy is also reviewed. The trends, practical, and logistic aspects of intrathecal radionuclide therapy of LM are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Iacoangeli M, et al. Intrathecal chemotherapy for treatment of overt meningeal leukemia: comparison between intraventricular and traditional intralumbar route. Ann Oncol. 1995;6(4):377–82.

    Article  CAS  PubMed  Google Scholar 

  2. Grossman SA, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73(5):641–7.

    Article  CAS  PubMed  Google Scholar 

  3. Goodwin DA, et al. Preparation, physiology, and dosimetry of 111 In-labeled radiopharmaceuticals for cisternography. Radiology. 1973;108(1):91–8.

    Article  CAS  PubMed  Google Scholar 

  4. Lette J, et al. A reproducible radionuclide procedure for measurement of cerebrospinal fluid shunt flow. Eur J Nucl Med. 1986;12(5–6):240–3.

    Article  CAS  PubMed  Google Scholar 

  5. Hosain F, Reba RC, Wagner HN Jr. Ytterbium-169 diethylenetriaminepentaacetic acid complex. A new radiopharmaceutical for brain scanning. Radiology. 1968;91(6):1294. passim.

    Article  PubMed  Google Scholar 

  6. Larson SM, et al. The radionuclide ventriculogram. JAMA. 1973;224(6):853–7.

    Article  CAS  PubMed  Google Scholar 

  7. Rebischung C, et al. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR. Int J Radiat Biol. 2008;84(12):1123–9.

    Article  CAS  PubMed  Google Scholar 

  8. de Rougemont J, et al. [Outflow in ventricular peritoneal derivations. Its determination with Na 131-I]. Neurochirurgie. 1970;16(4):307–18.

    Google Scholar 

  9. Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Kim S, Puduvali V, Hsu S, Kim EE. Toxicity and efficacy profiles of intrathecal injection of I-131 NaI via intraventricular (IVent) or intralumbar (Ilumb) route for leptomeningeal metastases (LM) therapy. J Clin Oncol. 2006;24(18S):70s.

    Google Scholar 

  10. Dichiro G, Reames PM, Matthews WB Jr. Risa-ventriculography and risa-cisternography. Neurology. 1964;14:185–91.

    Article  CAS  PubMed  Google Scholar 

  11. Bergstrand G, et al. Positron emission tomography with 68Ga-EDTA in the diagnosis and localization of CSF fistulas. J Comput Assist Tomogr. 1982;6(2):320–4.

    Article  CAS  PubMed  Google Scholar 

  12. Maziere B, et al. [55Co]- and [64Cu]DTPA: new radiopharmaceuticals for quantitative tomocisternography. Int J Appl Radiat Isot. 1983;34(3):595–601.

    Article  CAS  PubMed  Google Scholar 

  13. Freesmeyer M, et al. High-resolution PET cisternography with 64Cu-DOTA for CSF leak detection. Clin Nucl Med. 2019;44(9):735–7.

    Article  PubMed  Google Scholar 

  14. Muriel FS, et al. Remission maintenance therapy for meningeal leukaemia: intrathecal methotrexate and dexamethasone versus intrathecal craniospinal irradiation with a radiocolloid. Br J Haematol. 1976;34(1):119–27.

    Article  CAS  PubMed  Google Scholar 

  15. Metz O, Stoll W, Plenert W. Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer. 1982;49(2):224–8.

    Article  CAS  PubMed  Google Scholar 

  16. Lashford LS, et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer. 1988;61(5):857–68.

    Article  CAS  PubMed  Google Scholar 

  17. Bigner DD, Brown M, Coleman RE. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2–a preliminary report. J Neurooncol. 1995;24(1):109–22.

    Article  CAS  PubMed  Google Scholar 

  18. Kramer K, Humm JL, Souweidane MM. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25(34):5465–70.

    Article  PubMed  Google Scholar 

  19. Pandit-Taskar N, et al. Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors. J Nucl Med. 2019;60(12):1794–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Harbert JC. Intrathecal radiocolloids in meningeal leukemia. In: Harbert JC, Eckelman WC, Neumann RD, editors. Nuclear medicine: diagnosis and therapy. Thieme; 1996. p. 1157–61.

    Google Scholar 

  21. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer. 1999;85(4):980–7.

    Article  CAS  PubMed  Google Scholar 

  22. Halperin E, Fallat M, Bond S, Crew J, et al. Role of 32P-chromic phosphate colloids in the treatment of Askin tumors, Ewing’s sarcoma. J Nucl Med. 2012;53:1079.

    Google Scholar 

  23. Gold LH, et al. Current status of intrathecal radiogold in the treatment of medulloblastoma. Acta Radiol Ther Phys Biol. 1972;11(4):329–40.

    Article  CAS  PubMed  Google Scholar 

  24. Doge H, Hliscs R. Intrathecal therapy with 198Au-colloid for meningosis prophylaxis. Eur J Nucl Med. 1984;9(3):125–8.

    Article  CAS  PubMed  Google Scholar 

  25. Tjuvajev JG, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med. 1994;35(9):1407–17.

    CAS  PubMed  Google Scholar 

  26. Roelcke U, et al. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas. J Nucl Med. 2002;43(11):1444–51.

    CAS  PubMed  Google Scholar 

  27. Gutin PH, et al. Perfusion and molecular modification of idoxuridine to alter its cerebrospinal fluid metabolism. J Pharm Sci. 1977;66(9):1338–40.

    Article  CAS  PubMed  Google Scholar 

  28. Kassis AI, Dahman BA, Adelstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5. Acta Oncol. 2000;39(6):731–7.

    Article  CAS  PubMed  Google Scholar 

  29. Abdel-Nabi HH, Doerr RJ. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma. Target Diagn Ther. 1992;6:73–88.

    CAS  Google Scholar 

  30. Wiseman GA, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39(1–2):181–94.

    Article  CAS  PubMed  Google Scholar 

  31. Rutar FJ, et al. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin’s lymphoma based on radiation doses to family members. Clin Lymphoma. 2001;2(3):164–72.

    Article  CAS  PubMed  Google Scholar 

  32. Moseley RP, et al. Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry. 1991;54(3):260–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Richardson RB, et al. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med. 1990;17(1–2):42–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kramer K, et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatr Blood Cancer. 2018;65(1):e26754.

    Article  Google Scholar 

  35. Ingrand J. Characteristics of radio-isotopes for intra-articular therapy. Ann Rheum Dis. 1973;32 Suppl 6(Suppl):3–9.

    Article  Google Scholar 

  36. Black KC, et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano. 2014;8(5):4385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Mairs RJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer. 2000;82(1):74–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author is a co-principal investigator of MD Anderson Cancer Center protocol 2020-0595 using Lu-177 DTPA-Omburtamab. Sponsoring of Protocol 2020-0595 by Y mabs Inc. for the Lu-177 DTPA-Omburtamab trial (301 trial) is greatly appreciated. The author also thanks Dr. Zsilla Sadighi from MDACC pediatric neurology, the protocol principal investigator for making this protocol possible.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Franklin C. L. Wong

Authors
  1. Franklin C. L. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franklin C. L. Wong .

Editor information

Editors and Affiliations

  1. Dept of Nuclear Med, Unit No 1483, U Texas MD Anderson Cancer Ctr, Houston, TX, USA

    Franklin C.L. Wong

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wong, F.C.L. (2022). Radionuclide Leptomeningeal Metastasis Therapy Trials. In: Wong, F.C. (eds) Radiopharmaceuticals in the Management of Leptomeningeal Metastasis. Springer, Cham. https://doi.org/10.1007/978-3-031-14291-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14291-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14290-1

  • Online ISBN: 978-3-031-14291-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation